Brixton Biosciences, a spin-out from Massachusetts General Brigham, is a clinical stage life sciences company that develops novel therapies for treating pain. Its leadership team comprises experienced managers and key medical advisors, enabling a patient-centric strategy driven by the best of the best.
Market
Pain Management
Location
Cambridge,
MA,
USA
Coinvestors
Catalyst Health Ventures, Excelestar Ventures, PV Capital Management, Schooner Capital, Sparta Group, SV Health Investors